KCT0005894已完成未知
Colon cleansing efficacy and safety with 1 L Plenvu® versus 2 L CLICOOL®: Phase IV, multicenter, randomized, evaluator-blinded study
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 360
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 18(Year) 至 80(Year)（—）
- 性别
- All
入选标准
- •Patients 18 to 80 years of age who had scheduled for colonoscopy and signed the written informed consent form.
排除标准
- •1.diagnosed with colorectal cancer and inflammatory bowel disease (IBD)
- •2.has undergone a bowel resection
- •3.Pregnant or nursing woman
- •4.with severe renal failure (creatinine cleavage <30mL/min)
- •5.have undergone colon endoscopy within 6 months of consent date
- •6.participated in other clinical trials within 6 months of the consent date
- •7.Should not be included in this study for any reason of the PI’s judgement.
研究者
相似试验
已完成
不适用
A comparative study of the bowel cleansing between 1L-PEG and 2L-PEGFactors influencing health status and contact with health servicesKCT0006313Korea University Anam Hospital250
已完成
不适用
Comparison of coloninc cleansing methods for patients undergoing surgery of colorectal cancercolorectal cancerJPRN-UMIN000016693Keio University School of Medicine200
进行中（未招募）
1 期
COMPARAISON OF THE EFFICACY, SAFETY AND TOLERABILITY OF EZICLEN®/IZINOVA® VERSUS KLEAN-PREP® ON BOWEL CLEANSING IN ADOLESCENTS AGED 12-17 YEARS >40 KG UNDERGOING COLONOSCOPY.EUCTR2016-002265-60-CZIpsen Pharma250
已完成
3 期
Efficacy, safety and tolerability of a bowel cleansing preparation (Eziclen®/Izinova®)<br>in paediatric subjects undergoing colonoscopy: a Phase III, multicentre, randomised, comparative study versus Klean-Prep® (PEG-Electrolytes), administered on the day before colonoscopy,<br>Investigator-blinded, non-inferiority in adolescents of 12 to 17 years of age (inclusive) > 40 kg.<br>NL-OMON49151Ipsen Pharmaceuticals65
招募中
不适用
The efficacy and time of bowel cleansing agent for bowel preparation for colonoscopy among young and non constipated patientsColon tumorJPRN-UMIN000017112Osaka medical center for cancer and cardiovascular diseases.110